Daily Updates 10/07/25
$SPRB rose after FDA granted Breakthrough Therapy status to tralesinidase alfa for Sanfilippo B. US approval filing planned for Q1 2026. #biotech
www.biopharmcatalyst.com/news/2025/sp...
07.10.2025 20:32 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 10/07/25
$BMEA raises $25.3M via public offering at $2.05/unit, selling 11.2M shares & 1M pre-funded warrants; 3-year warrants exercisable at $2.50. 30-day option for more shares/warrants.
www.biopharmcatalyst.com/news/2025/sp...
07.10.2025 12:40 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 10/06/25
$BMEA: Icova Phase II shows 1.8% HbA1c drop at 9 months, works in GLP-1 failures, safe; new Phase II trials start Q4 2025.
www.biopharmcatalyst.com/news/2025/st...
06.10.2025 20:31 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 10/06/25
$SKYE: Nimacimab missed Phase 2a solo weight loss goal, but combo with semaglutide showed significant extra loss, safe profile. Advancing combo in obesity.
www.biopharmcatalyst.com/news/2025/sk...
06.10.2025 12:40 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 10/03/25
$EVAX to share new EVX-01 biomarker & immune data at SITC 2025; 2-yr Phase 2 KEYTRUDA combo results at ESMO 2025. More biotech news: $PALI $ANRO $OVID $IMAB $BOLT $APLIF $CLNN $SPRC $OCEA
www.biopharmcatalyst.com/news/2025/al...
03.10.2025 20:30 — 👍 0 🔁 0 💬 0 📌 0
BioPharmCatalyst Weekly Watchlist: Top biotech stocks with Phase 1/2 catalysts in 6 months. Key tickers: IFRX, BCYC, SNY, CYBN. #biotech #stocks www.biopharmcatalyst.com/news/2025/bi...
03.10.2025 20:15 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 10/03/25
$ANRO gets FDA Fast Track for ALTO-101 in schizophrenia cognitive impairment—no approved therapies yet, supporting faster development. $PALI $OVID $IMAB $QNTM $JAZZ $CLPT $DBVT $ZYBT $ADGM
www.biopharmcatalyst.com/news/2025/pa...
03.10.2025 12:40 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 10/02/25
$TSHA gets FDA Breakthrough Therapy status for TSHA-102 gene therapy in Rett syndrome; pivotal trial protocol aligned for upcoming BLA. More biotech news below.
www.biopharmcatalyst.com/news/2025/ta...
02.10.2025 20:30 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 10/02/25
$NBTX: Phase 1 data in esophageal cancer showed 85% disease control, 69% response. Well tolerated. More patients enrolling. Presented at ASTRO 2025.
www.biopharmcatalyst.com/news/2025/na...
02.10.2025 13:15 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 10/01/25
$APLIF & Vitalex get up to $40M NIAID funding for VXV-01 fungal vaccine, supporting manufacturing, preclinical, IND, and Phase 1 trials over 5 years.
www.biopharmcatalyst.com/news/2025/pa...
01.10.2025 20:31 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 10/01/25
$FBIO falls after FDA cites manufacturing issues for CUTX-101; no efficacy/safety concerns. Sentynl to fix and resubmit for Menkes disease.
www.biopharmcatalyst.com/news/2025/fo...
01.10.2025 12:40 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 09/30/25
$ANAB to split into two public companies by 2026: one for royalties/milestones, one for immunology drugs. Virtual event for ANB033 on Oct 14. #biotech
www.biopharmcatalyst.com/news/2025/sc...
30.09.2025 20:31 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 09/30/25
$ADXN posts Q2 net loss of 1.84M CHF (−0.02/share), down from 12.88M CHF profit last year. #Premarket $SPRC $QLGN $NLSP $BIAF $ARTL $PHIO $IPHA $SILO $SCYX
www.biopharmcatalyst.com/news/2025/n2...
30.09.2025 12:40 — 👍 0 🔁 0 💬 0 📌 0
$ENTA reported Phase 2b data for zelicapavir in high-risk RSV outpatients, showing clinically meaningful symptom resolution improvements across multiple endpoints.
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/en...
29.09.2025 20:34 — 👍 1 🔁 0 💬 0 📌 0
Pre-Market Updates 09/29/25
$DWTX acquires rights to SP16 in stock deal (7.31% equity). Phase 1b trial for CIPN starts 1H 2026; Halneuron Phase 2b interim data due Dec 2025. $MRUS $RDHL $MLTX $APLT $IOBT $PSTV $POAI $LRMR $CLLS
www.biopharmcatalyst.com/news/2025/ge...
29.09.2025 12:40 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 09/26/25
$BIAF’s CyPath Lung test detected early Stage 1A lung cancer & avoided invasive procedures, proving useful when imaging is unclear. #BiotechUpdates
www.biopharmcatalyst.com/news/2025/le...
26.09.2025 20:30 — 👍 0 🔁 0 💬 0 📌 0
BioPharmCatalyst Weekly #Watchlist: Top biotech stocks & Phase 3 catalysts in next 6 months. $COGT $RZLT $DVBT $BLTE $IMVT $TGTX. Full list: biopharmcatalyst.com/news/2025 www.biopharmcatalyst.com/news/2025/bi...
26.09.2025 20:15 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 09/26/25
$LEXX to sell 2.67M shares at $1.50/share in a direct offering. #BiotechNews $PEPG $SPRC $EVAX $PSTV $IMRX $RENB $VINC $LPTX $ZYBT $CURX
www.biopharmcatalyst.com/news/2025/le...
26.09.2025 18:14 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 09/26/25
$BIAF: CyPath Lung test detected Stage 1A lung cancer early, helped avoid invasive procedures in 2 cases, boosting diagnostic value.
www.biopharmcatalyst.com/news/2025/so...
26.09.2025 18:14 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 09/22/25
$PFE to buy $MTSR for up to $70/share (cash + CVRs), boosting obesity pipeline; deal valued at $7.2B. $QLGN $MBX $HSDT $KOD $CYCN $HOWL $THAR $SPRC
www.biopharmcatalyst.com/news/2025/qu...
22.09.2025 20:30 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 09/22/25
$PFE to buy $MTSR for up to $70/share ($7.2B total), boosting obesity and cardiometabolic pipeline. $QLGN $MBX $MTSR $CCCC $HSDT $GRI $TARA $GPCR $THAR $BRTX
www.biopharmcatalyst.com/news/2025/qu...
22.09.2025 12:40 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 09/19/25
$SABS shares promising SAB-142 data at EASD, advancing Phase 2b trial in new-onset Type 1 diabetes. Strengthens clinical & advocacy ties. #biotech #T1D
www.biopharmcatalyst.com/news/2025/re...
19.09.2025 20:30 — 👍 0 🔁 0 💬 0 📌 0
BioPharmCatalyst Weekly Watchlist: Biotech movers to watch as Q3 ends. Key tickers: $TGTX, $ZYNE, $FBIO, more. Get daily updates & catalysts! www.biopharmcatalyst.com/news/2025/bi...
19.09.2025 20:15 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 09/19/25
$RVPH raised $9M via a 27M share offering at $0.335/share to fund its CNS, inflammatory, and cardiometabolic drug pipeline.
www.biopharmcatalyst.com/news/2025/re...
19.09.2025 12:40 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 09/18/25
$REPL held a Type A FDA meeting on RP1+nivolumab BLA; no clear accelerated approval path yet. Reviewing feedback for next steps.
www.biopharmcatalyst.com/news/2025/ro...
18.09.2025 20:31 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 09/18/25
$ETNB to be acquired by Roche for $14.50/share cash + up to $6.00/share CVR, maximizing potential equity value.
www.biopharmcatalyst.com/news/2025/89...
18.09.2025 12:40 — 👍 1 🔁 0 💬 0 📌 0
BioPharmCatalyst Weekly Watchlist: Key PDUFA dates left this quarter. Top biotech stocks: $TGTX, $ZYNE, $MLTX, $BNOX, $FBIO, $SGMT, $ATYR, $PRAX, $SRRK, $CRNX. www.biopharmcatalyst.com/news/2025/bi...
18.09.2025 09:37 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 09/17/25
$SPRC jumps after AutoMax merger faces court delay due to deal uncertainties. Stay granted amid closing condition concerns. #BiotechUpdates
www.biopharmcatalyst.com/news/2025/sc...
17.09.2025 20:30 — 👍 0 🔁 0 💬 0 📌 0
Pre-Market Updates 09/17/25
$ORKA's Phase 1 data: ORKA-001, a long-acting IL-23p19 antibody, shows positive interim results.
www.biopharmcatalyst.com/news/2025/or...
17.09.2025 12:40 — 👍 0 🔁 0 💬 0 📌 0
Daily Updates 09/16/25
$CODX inks MoU for JV in MENA to license & commercialize its diagnostics tech, mirroring its India strategy. Expansion move!
www.biopharmcatalyst.com/news/2025/co...
16.09.2025 20:30 — 👍 0 🔁 0 💬 0 📌 0
Reporter/editor/narrative coach @Bloomberg.com. Co-author, Unbelievable. Law school dropout/honorary doctor. Formers: ProPublica, Marshall Project, Seattle Times. Perturbable.
https://kenarmstrongwriter.com/
Biotech investor & board member | Covering biotech, drug development, venture capital, startups and pharma |📍New York
https://www.linkedin.com/in/rubensebastianperez/
Covering biotech startups and VCs at BioPharma Dive. Hobbyist baker and dog wrangler.
Unofficial bot sharing alerts from FDA MedWatch.
This account is not monitored. Contact @wandrme.paxex.aero if needed.
Yes, it’s really us!
Our posts are FDA-approved!
Visit us at https://www.fda.gov
MD Student, Investor, Builder writing adus.substack.com. Website www.subradata.com,
Still on Twitter @plainyogurt21
Executive Editor, BioCentury. Host, BioCentury This Week biotech podcast. Jersey Boy happily ensconced in Cali. Princeton. SAIS. Philly Eagles. Opinions=my own.
A bioengineer who believes in an abundant future. Follow my writing on innovation at: https://gairiksachdeva.substack.com/
Biotech business development at Skyhook. Previously at Arbor Bio, Abata Tx, Silver Lab.
All views here and on Substack are my own.
CEO @AllayTx | Biotech, STEM & Skiing Interests & Tweets are my own
Biotech journalist; Senior Editor, BioPharma Dive. Former Deputy Biotech Editor, Xconomy. #BioSky
Computational biologist in industry; views are my own. Wide interests in genomics, immunotherapy, pharmacology, biotech, single cell methods, and reproductive biology.
I don’t check this account often. Founder & CEO of www.SeaportTx.com developing new medicines for neuropsychiatric disorders. Co-founder Karuna Tx (KarXt/Cobenfy now at BMS). Founding CEO & Senior Advisor PureTech. Co founder/host @BiotechCH. Board of BIO
Postdoc at @karalis-lab.bsky.social - @institutducerveau.bsky.social
I create computational models to build hypothesis and make predictions.
Philosophy of science aficionado
Space biologist • Complex systems engineer • Computational designer • Artist • Analog astronaut
Scientist, writer, human.
PhD Neurophysiologist, NIH specialist, researcher, game designer, and artist.
Views are my own. DFTBA
#NIH #NINDS #NIMH #BRAIN #neuro #neuroscience #science #research #neurons #SciFi #cognition
reporting on the $, people & startups in the biotech world for Endpoints News | klahucik@endpointsnews.com | also coach high school XC + Track & Field team | askin Qs, joggin 26.2 | 🌎🏳️🌈🏃🏻♂️🗞️💨
threaty threats -- helping build research workflows into a soc product, but I don't speak for them on this acct. pretty good at bash scripts and strings. disclosures on my linkedin below
https://www.linkedin.com/in/alexlanstein/
Senior editor, Endpoints News
aneeshsathe.com
🧪🧬💻🤖🔬🦠🩺💊🐍
